TY - JOUR T1 - Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: A systematic review JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.190261 SP - jrheum.190261 AU - Keith Colaco AU - Vanessa Ocampo AU - Ana Patricia Ayala AU - Paula Harvey AU - Dafna Gladman AU - Vincent Piguet AU - Lihi Eder Y1 - 2019/08/15 UR - http://www.jrheum.org/content/early/2019/08/08/jrheum.190261.abstract N2 - Objective We performed a systematic review of the literature to describe current knowledge of cardiovascular risk prediction algorithms in rheumatic diseases. Methods A systematic search of MEDLINE, EMBASE, and Cochrane Central databases was performed. The search was restricted to original publications in English, had to include clinical cardiovascular events as study outcomes, assess the predictive properties of at least one cardiovascular risk prediction algorithm, and include patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA) or psoriasis. By design, only cohort studies that followed participants for cardiovascular events were selected. Results Eleven of 146 identified manuscripts were included. Studies evaluated the predictive performance of the Framingham Risk Score, QRISK2, SCORE, Reynolds Risk Score, PCE, Expanded cardiovascular Risk Score for RA (ERS-RA), and the Italian Progetto CUORE score. Approaches to improve predictive performance of general risk algorithms in RA patients included the use of multipliers, biomarkers, disease-specific variables, or a combination of these to modify or develop an algorithm. In both SLE and PsA patients, multipliers were applied to general risk algorithms. In studies of RA and SLE patients, efforts to include non-traditional risk factors, disease-related variables, multipliers and biomarkers largely failed at substantially improving risk estimates. Conclusion Our study confirmed that general risk algorithms mostly underestimate and at times overestimate cardiovascular risk in rheumatic patients. We did not find studies that evaluated models for psoriasis or AS, which further demonstrates a need for research in these populations. ER -